(NASDAQ: VYGR) Voyager Therapeutics's forecast annual revenue growth rate of 32.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Voyager Therapeutics's revenue in 2025 is $31,316,000.On average, 14 Wall Street analysts forecast VYGR's revenue for 2025 to be $2,015,002,644, with the lowest VYGR revenue forecast at $1,527,834,708, and the highest VYGR revenue forecast at $2,864,794,328. On average, 14 Wall Street analysts forecast VYGR's revenue for 2026 to be $3,461,327,629, with the lowest VYGR revenue forecast at $217,952,329, and the highest VYGR revenue forecast at $8,228,812,432.
In 2027, VYGR is forecast to generate $3,798,653,339 in revenue, with the lowest revenue forecast at $516,024,380 and the highest revenue forecast at $7,176,858,843.